CFAH ESMO’s 2021 virtual Congress, 16 -21 September: a pick of VHIO research highlights – VHIO – Vall d'Hebron Institute of Oncology

ESMO’s 2021 virtual Congress, 16 -21 September: a pick of VHIO research highlights

With the 2021 annual Congress of the European Society for Medical Oncology (ESMO) just around the corner, we have delved into its superb scientific program and selected a handful of VHIO – Vall d’Hebron University Hospital (co) led studies that are set to showcase during this virtual meeting par excellence:

A duo of Presidentials

During the Congress’ first Presidential Symposium co-chaired by ESMO and ESMO Congress President, Solange Peters (Lausanne, Switzerland), and ESMO’s President Elect, Andrés Cervantes (Valencia, Spain), Javier Cortés will present results of the randomized phase III DESTINY-Breast03 study.

This pioneering study was designed to compare the anti-tumor activity as well as the safety and efficacy of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with unresectable or metastatic HER2-positive metastatic breast cancer, previously treated with trastuzumab and taxane.

Javier Cortés, PI of this multi-center study, Director of the International Breast Cancer Center, Quiron Group (Madrid & Barcelona, Spain), and an Associate Translational Investigator at VHIO, will present and discuss the data on Channel 1 at 15:05 – 15:20h (CEST).

Link to the respective session, abstract number & title:

Presidential Symposium 1

Saturday 18 September, 15:05-16:35h

LBA1 – Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study.

Latest data from the from the phase III IMpower010 global trial, primary results of which were presented earlier this year at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, 04 – 08 June, will be presented by co-lead investigator Enriqueta Felip, Principal Investigator of VHIO’s Thoracic Tumors & Head and Neck Group, and Head of the Thoracic Cancer Unit at the Vall d’Hebron University Hospital (HUVH – Vall d’Hebron Barcelona Hospital Campus).

This pivotal trial is the very first phase III study to assess the efficacy of immunotherapy atezolizumab in patients with resected, stage II-III, non-small cell lung cancer (NSCLC).

Leading to a paradigm shift in the treatment of this tumor type? Discover the latest data by tuning into Channel 1 for Enriqueta’s presentation, 16:10-16:25h (CEST) during Presidential Symposium 3, co-chaired by Solange Peters and Congress Co-Chair, Pasi A. Jänne, Dana Farber Cancer Institute, Boston, MA (USA).

Link to the respective session, abstract number & title:

Presidential Symposium 3

Monday 20 September, 15:05 – 16:35h

LBA9 – IMpower010: sites of relapse and subsequent therapy from a Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC.

________________________________________________________________

Promising advances in the treatment of breast cancer

In addition to the aforementioned phase III DESTINY-Breast03, VHIO investigators have also led and participated in other breast cancer studies that are about to headline during ESMO 2021.

Results from the phase III TULIP study will be presented by Cristina Saura, Principal Investigator of VHIO’s Breast Cancer Group, Sunday 19 September, 13:30 – 13:40h (CEST), Channel 1. Also selected as a Late-Breaking Abstract by ESMO, we invite you to virtually attend this oral presentation to discover how data from this multi-center clinical trial could contribute to the therapeutic arsenal for patients with pretreated HER-positive unresectable locally advanced or metastatic breast cancer.

Link to the respective session, abstract number & title:

Proffered Paper Session – Breast cancer, metastatic

Sunday 19 September, 13:30 – 13:40h

LBA15 – Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.

________________________________________________________________

Mafalda Oliveira, Medical Oncologist and Clinical Investigator of VHIO’s Breast Cancer Group, directed by Cristina Saura, will present results from the POSEIDON international, multicenter randomized phase II trial; a study that derived from the Cancer Core Europe (CCE) consortium. Also selected as a Late-Breaking Abstract,  the results assessing the addition of P13K inhibitor taselisib to hormonal therapy tamoxifen in patients with hormone receptor positive and HER2 negative metastatic breast cancer will be revealed on Saturday 18 September, 17:55-18:00h (CEST) on Channel 1.

Link to the respective session, abstract number & title:

Mini Oral Session – Breast cancer, metastatic

Saturday 18 September, 17:30 – 18:20h

LBA18 – POSEIDON randomized phase II trial: tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC).

________________________________________________________________

Javier Cortés is first author of the final results from the KEYNOTE-355 randomized, double-blind phase III study of first-line immunotherapy, pembrolizumab, plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer whose tumors expressed PD-L1.

Selected by ESMO as a Proffered Paper on Sunday 19 September, Channel 1, 14:00-14:10h CEST, the data will be presented by co-author Hope S. Rugo, University of California San Francisco Comprehensive Cancer Center (CA, USA) during the following session:

Proffered Paper Session – Breast cancer, metastatic

Sunday 19 September, 13:30 – 14:55h

LBA16 – KEYNOTE-355: Final results from a randomized, double-blind phase 3 study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC.

________________________________________________________________

 COVID-19 & Cancer

Research directed by David J. Pinato, Imperial College London (UK), co-authored by Juan Aguilar, Internist in infectious diseases, the Vall d’Hebron University Hospital’s Medical Oncology Department, headed by Josep Tabernero, who is also a co-author and VHIO’s Director, assessed the impact and consequences of COVID-19 in European cancer patients. Specifically, data from more than 2000 cancer patients consecutively diagnosed with the virus during the different waves of the pandemic will be presented and discussed by David J. Pinato on Tuesday 21 September, on Channel 2 at 16:50-16:55h (CEST).

The researchers sought to establish whether mortality from COVID-19 in patients with cancer across Europe has improved over time, and also suggest possible factors behind identified trends.

Link to the respective session, abstract number & title:

Mini Oral Session – SARS-CoV-2 and cancer

Tuesday 21 September, 16:20 – 17:20h

1565MO – Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry.

________________________________________________________________

Treatment advances against NETs & endocrine tumors

During a Mini Oral Session, Monday 20 September, Channel 5, 17:30 – 17:35h CEST, Jaume Capdevila, Medical Oncologist and Clinical Investigator of VHIO’s Gastrointestinal and Endocrine Tumors Group (Director, Josep Tabernero, PI: Teresa Macarulla), will present the final results from the double-blind phase III COSMIC-311 study which evaluated the efficacy and safety of cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who had progressed during/after prior VEGFR-targeted therapy for whom there is no standard of care.

Headlining earlier this year, the interim results of COSMIC-311 were presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, 04 – 08 June. Achieving the primary endpoint of progression-free survival (PFS), in all randomized patients including those who had previously received lenvatinib, cabozantinib showed clinical and statistical improvements in PFS over placebo, with no unexpected toxicities.

Will results from the final analysis deliver on the promise of a new standard of care for patients with previously treated differentiated thyroid cancer? We invite you to tune in to Channel 5 to find out!

Link to the respective session, abstract number & title:

Mini Oral Session – NETs and endocrine tumours

Monday 20 September, 17:30 – 18:20h

LBA67 – Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses by prior therapy.

________________________________________________________________

Joining Jaume Capdevila as a fellow presenter at the this same Mini Oral Session, is Jorge Hernando, also a Medical Oncologist and Clinical Investigator of VHIO’s Gastrointestinal and Endocrine Tumors Group.

At 17:50-17:55h CEST Jorge Hernando will present the latest data from the multi-cohort phase II DUNE trial assessing the combination of durvalumab plus tremelimumab and influence on response to subsequent treatments in patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origins.

To discover the activity of systemic therapies after progression on immune checkpoint blockade in the DUNE trial, we invite you to add this session to your ESMO Congress diary:

Mini Oral Session – NETs and endocrine tumours

Monday 20 September, 17:30 – 18:20h

1099MO – Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601).

________________________________________________________________

Jaume Capdevila is also a co-author of the AXINET phase II/III study designed to assess the efficacy of axitinib in combination with octreotide LAR versus placebo and octreotide LAR in patients with advanced G1-2 extra-pancreatic NETs.

Earlier findings from this study were reported by lead author Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Madrid (Spain), at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021. Results showed that while the study failed to demonstrate a significant progression-free survival (PFS) benefit per investigator assessment, axitinib in combination with octreotide LAR demonstrated activity and had a tolerable safety profile in this patient population.

What’s next? Upon subsequent central blinded radiological PFS assessment studies, we’ll find out by tuning into Channel 3 for the following session:

Proffered Paper Session – NETs and endocrine tumours

Tuesday 21 September, 13:30 – 14:50h CEST

Channel 3

1097O – The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs.

Speaker: Rocio Garcia-Carbonero

Lecture Time: 14:20 – 14:30h

________________________________________________________________

COAST: delivering on the promise of immunotherapy against NSCLC?

Selected by ESMO as a Late Breaker, the COAST phase II is an open-label, multicenter, randomized multidrug platform trial.  This study was designed to assess the efficacy and safety of immunotherapy durvalumab alone versus durvalumab in combination with novel agents in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC), who have not progressed after concurrent chemoradiotherapy (cCRT).

Just how well does this immune-based therapy fair either ‘going solo’ or in combination? Alexandre Martínez-Martí, Medical Oncologist and Clinical Investigator of VHIO’s Thoracic Tumors & Head and Neck Group, will reveal latest results  on Friday 17 September, Channel 2, 14:20 – 14:30h CEST.

Link to the respective session, abstract number & title:

 Proffered Paper Session – Non-metastatic NSCLC and other thoracic malignancies

Friday 17 September, 13:30 – 14:50h

LBA42COAST: an open-label, randomised, phase 2 platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, Stage III NSCLC.

________________________________________________________________

DESTINY-CRCO1: exploratory biomarker analysis in tumor and liquid biopsy

Results previously reported at at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, 04 – 08 June, from the  the phase II DESTINY-CRC01 trial showed that trastuzumab deruxtecan-nxki produced durable responses in patients with previously treated HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with that reported in previous trastuzumab deruxtecan trials.

The study investigators, including Elena Élez, Medical Oncologist and Clinical Investigator of VHIO’s Gastrointestinal and Endocrine Tumors Group, and coordinator of colorectal cancer research, have now performed exploratory biomarker analysis in tumor and liquid biopsy to seek out potential mechanisms of resistance and response towards more precisely matching patients to this particular treatment. Results will be presented by lead author Salvatore Siena, Università degli Studi di Milano (Milan, Italy), Saturday 18 September at 13:40 – 13:50h CEST, Channel 2.

Link to the respective session, abstract number & title:

Proffered Paper session – Gastrointestinal tumours, colorectal 1

Saturday 18 September, 13:30 – 14:50h

386O – Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC).

________________________________________________________________

Throughout the course of the ESMO Congress 2021, VHIO investigators are lead/co-authors of several other additional contributions including those that have been selected to showcase as ePosters.

As examples, during the Colorectal Cancer track, under the supervision of Elena Élez, Iosune Baraibar, a Medical Oncologist and Clinical Investigator of VHIO’s Gastrointestinal and Endocrine Tumors Group, will present a study on molecular tumor profiling and matched molecular targeted treatment towards the more effective treatment of metastatic young-onset colorectal cancer (YOCR).

Link to this ePoster:

461P– Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR).

________________________________________________________________

Francisco Javier Ros, Medical Oncologist and Clinical Investigator of the same group, will present an ePoster on prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor.

Link to this ePoster:

445P – Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor.

________________________________________________________________

Under the supervision of Medical Oncologist and Clinical Investigator, Francesc Salvà, and co-authored by other researchers of VHIO’s Gastrointestinal and Endocrine Tumors Group, as well as other teams, Augusto A. Valdivia will present an ePoster on the role of clinical prognostic characteristics as a potential stratification tool to more effectively determine which patients with refractory metastatic colorectal cancer (refMCRC) would benefit from late-line therapies.

Link to this ePoster:

426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care.

________________________________________________________________

Another study led by researchers at VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch and Early Clinical Drug Development Group, both championed by Elena Garralda, will also first outing as an ePoster during the meeting.

Early phase Investigator, Omar Saavedra Santa Gadea, will present results from a phase II trial assessing the efficacy of combining A2AR antagonist taminadenant with immune-based therapy spartalizumab in patients with microsatellite stable (MSS) colorectal cancer (CRC).

Link to this ePoster:

436P – Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC).

________________________________________________________________

A study led by investigators at VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, directed by Elena Garralda, explored the impact of the COVID-19 pandemic on the start-up activities of the phase I Unit. Presented by Maria Julia Lostes Bardaji, phase I Investigator at the UITM, and Silvia Perez-Pujol, Head of VHIO’s Start Up Unit, while data show an initial decrease in new clinical studies during 2020, digitalization and measures in place proved effective in maintaining activity; leading to an increase in the number of new proposals for phase I studies in 2021.

Link to this ePoster:

1623P – Phase I clinical trials (CT) forge on despite COVID-19.

________________________________________________________________

In early stage breast cancer, Nadia Saoudi, a Medical Oncologist and Clinical Investigator of our Breast Cancer Group (PI: Cristina Saura), will present data from meta-analysis of the prognostic value of circulating tumor DNA.

Link to this ePoster:

152P – Meta-analysis of the prognostic value of circulating tumor DNA (ctDNA) in patients (pts) with early breast cancer (EBC).

________________________________________________________________

In collaboration with researchers of VHIO’s Experimental Therapeutics directed by Violeta Serra, Benedetta Pellegrino, a Medical Oncologist at the University Hospital of Parma (Italy), will present an ePoster on the prognosis of high-risk breast cancer with RAD51-low levels.

Link to this ePoster:

145P – High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis.

________________________________________________________________

In addition to the studies that have counted on the participation of VHIO faculty, many of our investigators have also been selected as chairs and/or discussants during a variety of ESMO Congress sessions, as well as trigger essential debate at the Controversies.

Highlights plus links to respective sessions:

Thursday, 16 September

Educational Session

What is the optimal continuum of care in 2021 in colorectal cancer? 

VHIO’s participation:

Session Chair: Josep Tabernero, VHIO’s Director, Past-President of ESMO.

Speaker: Elena Élez, Medical Oncologist & Clinical Investigator, VHIO’s Gastrointestinal & Endocrine Tumors Group.

Talk title: Targeted agents for small subgroups: When and how?  (ID 104).

Multidisciplinary session

Successful strategies for tumour agnostic treatment approaches

VHIO’s participation:

Chair: Elena Garralda, Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Principal Investigator, Early Clinical Drug Development Group.

Special Symposium

Fast-track prostate cancer precision medicine development: Tools and caveats

VHIO’s participation:

Speaker: Raquel Perez-Lopez, Principal Investigator, VHIO’s Radiomics Group.

Talk title: Precision imaging for the “elusive” prostate cancer and its implication for therapy development.

Special Symposium

New protein-based therapeutics 

VHIO’s participation:

Speaker: Elena Garralda, Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Principal Investigator, Early Clinical Drug Development Group.

Talk title: Monoclonal antibodies: Old and new targets.

Educational session

Testing for fusions: When and how? 

VHIO’s participation:

Speaker: Ana Vivancos, Principal Investigator, VHIO’s Cancer Genomics Group.

Talk title: The relative merits of different approaches to fusion testing (ID 86).

Educational session

Realising potential combination and personalised therapy

VHIO’s participation:

Speaker: Cristina Suárez, Medical Oncologist & Clinical Investigator, VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group (PI: Joan Carles).

Talk title: Future targets and combinations for mRCC (ID 145).

________________________________________________________________

Friday, 17 September

Special session

ESMO Women for Oncology Award 2021

VHIO’s participation:

Chair: Josep Tabernero, VHIO’s Director, Past-President of ESMO.

Proffered Paper session

Proffered Paper session – Developmental therapeutics

VHIO’s participation:

Invited Discussant 513O and 514O: Elena Garralda, Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Principal Investigator, Early Clinical Drug Development Group.

________________________________________________________________

Saturday, 18 September

Proffered Paper session

Proffered Paper session – Genitourinary tumours, prostate

VHIO’s participation:

Invited Discussant 577O: Joaquin Mateo, Principal Investigator, VHIO’s Prostate Cancer Translational Research Group.

Controversy session

All patients with newly diagnosed mBC should receive a comprehensive profiling using multigene sequencing

VHIO’s participation:

Speaker: Cristina Saura, Principal Investigator, VHIO’s Breast Cancer Group.

________________________________________________________________

Sunday, 19 September

Presidential Symposium

Presidential Symposium 2 – Discussion session II: Gastrointestinal tumours

VHIO’s participation:

Chair, Q&A and live discussion: Josep Tabernero, VHIO’s Director, Past-President of ESMO.

Mini oral session

Mini oral session – Gynaecological cancers

VHIO’s participation:

Discussion 723MO and 724MO: Ana Oaknin, Principal Investigator, VHIO’s Gynecological Malignancies Group.

________________________________________________________________

Monday, 20 September

Mini oral session

Mini oral session – CNS tumours

VHIO’s participation:

Speaker: Maria Vieito, Medical Oncologist & Clinical Investigator, VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group (PI: Joan Carles).

Presentation: 344MO Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma.

________________________________________________________________

Tuesday, 21 September

Special session

ESMO Guidelines

VHIO’s participation:

Speaker: Enriqueta Felip, Principal Investigator, VHIO’s Thoracic Tumors & Head and Neck Cancer Group.

Discussion of case 2: Patient with early, resected EGFR-mutated NSCLC and subsequent relapse.

13/09/2021|